#surrogateendpoints search results
New low on Twitter - people complaining about clinicians criticizing studies because they “don’t design studies.” We are the clinicians. GTFO. Don’t design bad studies or change SOC based on #surrogateendpoints and we won’t have any issue! #meded #mmsm
Fabulous oncology grand rounds today by the inestimable Bishal Gyawali on how we need far more rigorous critical thinking when designing and interpreting oncology clinical trials #SurrogateEndpoints #Bias #Pvalues
Study review the role of #surrogateendpoints in #healthpolicy #decisions. ow.ly/Nhtb30aBOZ0 #HEOR #HTA
“You can cure a lot of mice with cancer, but that doesn’t always translate to humans” @DanaFarber @LGlimcherMD discusses the problem w #surrogateendpoints in cancer research in first panel conversation @AtlanticLIVE #peoplevcancer with @SurvivorNetTeam
The @npr #NPRShots recent report includes commentary from oncologist @oncology_bg and the study's author @VPrasadMDMPH. The report via @rrichardh is excellent! npr.org/sections/healt… #surrogateendpoints #research #cancer #oncology
Key #drugaccess issue for @EORTC is an appropriate recognition of innovation when #cancerdrugs are approved based on #surrogateendpoints with no available evidence on #overallsurvival. #newdeal4meds #drugdevelopment #accesstocare
Prof Rod Taylor and Dr @AnthonyManyara_ next to our poster on the new SPIRIT-and CONSORT-Surrogate extensions. If at #ictmc2024 come chat with Rod from 12:30pm on reporting surrogate endpoints, its poster number 213.#surrogateendpoints
📢New publication in the @JClinEpi as part of the SPIRIT|CONSORT-Surrogate project Definitions, acceptability, limitations, and guidance in the use and reporting of #surrogateendpoints in #RCTs: A scoping review doi.org/10.1016/j.jcli…
Pleasure to participate in @sitcancer #SurrogateEndpoints Summit today & colead #IO Endpoints WG w KOLs from @theNCI @US_FDA industry academia tackling #trialdesign #biomarkers #immunooncology Report to follow @MoffittNews
Learn and get hands on « Selecting outcomes: #SurrogateEndpoints » by Dr Antònia Agustí @univbordeaux #Eu2PFW @antonia_ficf @UABBarcelona @FundacioICF , and more on eu2p.org/short-courses/…
@EraEdtaRegistry Kitty Jagar outlines some of the problems with running RCTs in #nephrology #longtime #surrogateendpoints need to predict the clinical endpoint👆🏻 #eraedta19 @ERAEDTA @ynptweets @fjcaskey
Hello Twitter and happy new month! Glad to be here to report and update on our #SurrogateEndpoints reporting guidelines project. #FirstTweet
.@BettinaRyll rightly so disagrees at @EUAccessAcademy's convention that #SurrogateEndpoints are not valuable in the #HTA process. #CancerPatients celebrate any #stablescan. That is benefit! Additional stable scans eventually translate into #OverallSurvival. #PatientVoice
Starting now at #ISPOREurope, join us for Breakout session 4, focused on #HTA, #SurrogateEndpoints #Healthcare, #DigitalEndpoints. #HEOR ow.ly/A1Ya30riT9q
If attending @ictmc2022 #ICTMC2022 and interested in #surrogateendpoints reporting in trials, please help with developing the SPIRIT- and CONSORT-SURROGATE extensions. The Delphi survey closes this Friday the 7th and can be accessed using this link delphimanager.liv.ac.uk/consort-surrog…
Contribute to developing SPIRIT and CONSORT extensions for #trials that use #surrogateendpoints You can participate in the Delphi survey using this link 👇 delphimanager.liv.ac.uk/consort-surrog… #MethodologyMonday
How can we ensure that #surrogateendpoints used in accelerated regulatory and #HTA decisions are scientifically robust and reflect outcomes that matter to #patients? That's the topic of the final plenary of #ISPORAnnual 2025. What are your thoughts? ow.ly/LT1850VI4tX
How much do you know about #surrogateendpoints, #computablephenotypes, #digitaltherapeutics, #machinelearning, #populationhealth, #patientpreference, causal study designs, #socialdeterminants? Includes podium. Sharpen up on these topics now! #ISPORAnnual ow.ly/vqOl30sj4v5
Skills Lab: Why #SurrogateEndpoints Shouldn’t Justify Full Cancer Drug Approvals medscape.com/viewarticle/sk…
Skills Lab: Why #SurrogateEndpoints Shouldn’t Justify Full Cancer Drug Approvals medscape.com/viewarticle/sk…
How can we ensure that #surrogateendpoints used in accelerated regulatory and #HTA decisions are scientifically robust and reflect outcomes that matter to #patients? That's the topic of the final plenary of #ISPORAnnual 2025. What are your thoughts? ow.ly/LT1850VI4tX
Skills Lab: Classifying and Defining #SurrogateEndpoints for Clinical Trials medscape.com/viewarticle/sk…
The final plenary of #ISPORAnnual will examine the methodological approaches for ensuring that #surrogateendpoints used in accelerated regulatory & #HTA decisions are scientifically robust & reflect the #patients best interests. Hear from the experts! ow.ly/ranR50VHjvz
Skills Lab: Understanding #SurrogateEndpoints and Their Limitations medscape.com/viewarticle/sk…
Catch up on our webinar with @consiliumsci which addresses the challenges when implementing innovations in #CancerScreening and the use of #SurrogateEndpoints to indicate an impact on cancer outcomes. Watch on demand at a time that is convenient for you by clicking below 👇
#SurrogateEndpoints in oncology trials remain controversial. Our latest article answers 15 common questions, addressing pitfalls and the way forward. Learn why OS and QoL should be the gold standards. bit.ly/4dOqddM #ClinicalTrials @oncology_bg @TheLancet
Excellent summary by @oncology_bg on our recent paper on #SurrogateEndPoints in @eClinicalMed @TheLancet.
Surrogate endpoints in oncology trials remain controversial. Our latest article answers 15 common questions, addressing pitfalls and the way forward. Learn why OS and QoL should be the gold standards. bit.ly/4dOqddM #ClinicalTrials @oncology_bg @TheLancet
Prof Rod Taylor and Dr @AnthonyManyara_ next to our poster on the new SPIRIT-and CONSORT-Surrogate extensions. If at #ictmc2024 come chat with Rod from 12:30pm on reporting surrogate endpoints, its poster number 213.#surrogateendpoints
FINAL REPORT 👇now available from @sitcancer #SurrogateEndpoints Virtual Summit | Pleasure to co-lead #IO Endpoints Working Group | Tackling important questions for future #immunooncology #clinicaltrialdesign #drugdevelopment #biomarkers images.magnetmail.net/images/clients…
🆕publication in @TheLancet about the SPIRIT|CONSORT-Surrogate extensions: Transparent and complete reporting of surrogate endpoints in trials: the SPIRIT-Surrogate and CONSORT-Surrogate extensions. ➡️doi.org/10.1016/S0140-… #SurrogateEndpoints @Consort_surr @AnthonyManyara_
4/ Therefore, it is important that trials using #surrogateendpoints are adequately reported. Over the last 2.5 years, a multidisciplinary project group has led and coordinated the development of the SPIRIT-Surrogate and CONSORT-Surrogate #reportingguidelines
Exactly this is the reason why we need to work on intermediate and #SurrogateEndpoints @UroDocAsh Beyond surrogate endpoints we need better endpoints reflecting true #patient benefit, including less subsequent treatment, less urological interventions - all this matters beyond OS
Most oncology drugs granted accelerated approval did not demonstrate OS benefit or improve QOL within 5 years of approval Need better correlation of surrogate endpoints with what actually matters to patients jamanetwork.com/journals/jama/… @JAMAOnc @IBCG_BladderCA #EAU24 #AACR24
Pleasure to participate in @sitcancer #SurrogateEndpoints Summit today & colead #IO Endpoints WG w KOLs from @theNCI @US_FDA industry academia tackling #trialdesign #biomarkers #immunooncology Report to follow @MoffittNews
Just a reminder about our webinar with Rod Taylor about #SurrogateEndpoints 🗓️ 14th December 13:00-14:00 (CET) 🔗 syddanskuni.zoom.us/j/69338292259
New date for our webinar with Rod Taylor: "Surrogate Endpoints in Trials: Friend or Foe" 14th December 13:00-14:00 (CET) syddanskuni.zoom.us/j/69338292259 #SurrogateEndpoints have been heavily criticized, but perhaps they are warranted in some cases @Consort_surr @SUND_SDU @OUHhospital
New date for our webinar with Rod Taylor: "Surrogate Endpoints in Trials: Friend or Foe" 14th December 13:00-14:00 (CET) syddanskuni.zoom.us/j/69338292259 #SurrogateEndpoints have been heavily criticized, but perhaps they are warranted in some cases @Consort_surr @SUND_SDU @OUHhospital
Webinar with Rod Taylor: "Surrogate Endpoints in Trials: Friend or Foe" When: 7th November 15:00 to 16:00 (CET) Where: syddanskuni.zoom.us/j/69338292259 #SurrogateEndpoints have been heavily criticized, but perhaps they are warranted in some cases? @Consort_surr @SUND_SDU @OUHospitals
Looks like PFS curves in oncology! #surrogateendpoints 😎
Pleasure to participate in @sitcancer #SurrogateEndpoints Summit today & colead #IO Endpoints WG w KOLs from @theNCI @US_FDA industry academia tackling #trialdesign #biomarkers #immunooncology Report to follow @MoffittNews
Study review the role of #surrogateendpoints in #healthpolicy #decisions. ow.ly/Nhtb30aBOZ0 #HEOR #HTA
New low on Twitter - people complaining about clinicians criticizing studies because they “don’t design studies.” We are the clinicians. GTFO. Don’t design bad studies or change SOC based on #surrogateendpoints and we won’t have any issue! #meded #mmsm
Fabulous oncology grand rounds today by the inestimable Bishal Gyawali on how we need far more rigorous critical thinking when designing and interpreting oncology clinical trials #SurrogateEndpoints #Bias #Pvalues
Learn and get hands on « Selecting outcomes: #SurrogateEndpoints » by Dr Antònia Agustí @univbordeaux #Eu2PFW @antonia_ficf @UABBarcelona @FundacioICF , and more on eu2p.org/short-courses/…
“You can cure a lot of mice with cancer, but that doesn’t always translate to humans” @DanaFarber @LGlimcherMD discusses the problem w #surrogateendpoints in cancer research in first panel conversation @AtlanticLIVE #peoplevcancer with @SurvivorNetTeam
Key #drugaccess issue for @EORTC is an appropriate recognition of innovation when #cancerdrugs are approved based on #surrogateendpoints with no available evidence on #overallsurvival. #newdeal4meds #drugdevelopment #accesstocare
.@BettinaRyll rightly so disagrees at @EUAccessAcademy's convention that #SurrogateEndpoints are not valuable in the #HTA process. #CancerPatients celebrate any #stablescan. That is benefit! Additional stable scans eventually translate into #OverallSurvival. #PatientVoice
📢New publication in the @JClinEpi as part of the SPIRIT|CONSORT-Surrogate project Definitions, acceptability, limitations, and guidance in the use and reporting of #surrogateendpoints in #RCTs: A scoping review doi.org/10.1016/j.jcli…
The @npr #NPRShots recent report includes commentary from oncologist @oncology_bg and the study's author @VPrasadMDMPH. The report via @rrichardh is excellent! npr.org/sections/healt… #surrogateendpoints #research #cancer #oncology
@EraEdtaRegistry Kitty Jagar outlines some of the problems with running RCTs in #nephrology #longtime #surrogateendpoints need to predict the clinical endpoint👆🏻 #eraedta19 @ERAEDTA @ynptweets @fjcaskey
Starting now at #ISPOREurope, join us for Breakout session 4, focused on #HTA, #SurrogateEndpoints #Healthcare, #DigitalEndpoints. #HEOR ow.ly/A1Ya30riT9q
Prof Rod Taylor and Dr @AnthonyManyara_ next to our poster on the new SPIRIT-and CONSORT-Surrogate extensions. If at #ictmc2024 come chat with Rod from 12:30pm on reporting surrogate endpoints, its poster number 213.#surrogateendpoints
The final plenary of #ISPORAnnual will examine the methodological approaches for ensuring that #surrogateendpoints used in accelerated regulatory & #HTA decisions are scientifically robust & reflect the #patients best interests. Hear from the experts! ow.ly/ranR50VHjvz
How can we ensure that #surrogateendpoints used in accelerated regulatory and #HTA decisions are scientifically robust and reflect outcomes that matter to #patients? That's the topic of the final plenary of #ISPORAnnual 2025. What are your thoughts? ow.ly/LT1850VI4tX
🆕publication in @TheLancet about the SPIRIT|CONSORT-Surrogate extensions: Transparent and complete reporting of surrogate endpoints in trials: the SPIRIT-Surrogate and CONSORT-Surrogate extensions. ➡️doi.org/10.1016/S0140-… #SurrogateEndpoints @Consort_surr @AnthonyManyara_
Register today for IDDI complimentary Lunch&Learn ‘Validating Surrogate Endpoints in Oncology’, Museum of Science in Boston, October 8. Keynote Speaker: Prof. Christopher Sweeney. Register here: bit.ly/30E50hX #oncology #surrogateendpoints #clinicaltrials #boston #IDDI
Hello Twitter and happy new month! Glad to be here to report and update on our #SurrogateEndpoints reporting guidelines project. #FirstTweet
@IDDI_Official & Roche Identify DFS As Way Forward In Early Breast Cancer. Read Press Release here: appliedclinicaltrialsonline.com/iddi-roche-ide… #oncology #surrogateendpoints #biomarkers #biostatistics
Something went wrong.
Something went wrong.
United States Trends
- 1. Grammy 441K posts
- 2. #FliffCashFriday 2,502 posts
- 3. Vesia 3,069 posts
- 4. Dizzy 11.4K posts
- 5. #drwfirstgoal N/A
- 6. James Watson 12.2K posts
- 7. Georgetown 2,302 posts
- 8. Capitol Police 15.5K posts
- 9. Myles Rice N/A
- 10. Collar 14.8K posts
- 11. Dylan Edwards N/A
- 12. Chase 88.9K posts
- 13. MANELYK EN COMPLICES 17K posts
- 14. NBA Cup 5,451 posts
- 15. Filibuster 390K posts
- 16. Darryl Strawberry 1,810 posts
- 17. Silver Slugger 13.3K posts
- 18. Clipse 25.2K posts
- 19. Thank a Republican 1,001 posts
- 20. Laporta 14.8K posts